| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.33B | 36.29B | 30.45B | 35.38B | 37.30B | 32.89B |
| Gross Profit | 8.62B | 8.26B | 6.45B | 7.41B | 8.90B | 8.21B |
| EBITDA | 7.23B | 7.07B | 5.41B | 5.99B | 9.59B | 7.04B |
| Net Income | 2.90B | 2.89B | 1.84B | 2.28B | 5.36B | 2.96B |
Balance Sheet | ||||||
| Total Assets | 58.99B | 60.73B | 58.62B | 55.47B | 56.60B | 52.93B |
| Cash, Cash Equivalents and Short-Term Investments | 14.66B | 16.64B | 16.23B | 15.10B | 15.89B | 15.57B |
| Total Debt | 5.58B | 5.37B | 4.93B | 3.92B | 5.42B | 8.71B |
| Total Liabilities | 14.58B | 15.73B | 14.12B | 12.31B | 13.87B | 16.18B |
| Stockholders Equity | 44.18B | 44.75B | 44.26B | 42.92B | 42.22B | 36.27B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.95B | 683.00M | 1.05B | 2.68B | 4.92B |
| Operating Cash Flow | 0.00 | 7.12B | 6.54B | 5.63B | 5.40B | 7.35B |
| Investing Cash Flow | 0.00 | -4.32B | -5.83B | -3.28B | -5.67B | -2.46B |
| Financing Cash Flow | 0.00 | -2.83B | -141.00M | -3.72B | 94.00M | -3.00B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥64.28B | 13.15 | ― | 3.33% | 3.03% | 28.27% | |
77 Outperform | ¥84.40B | 16.84 | 10.57% | 1.82% | 15.12% | 40.72% | |
72 Outperform | ¥51.93B | 17.06 | 6.67% | 4.12% | 13.87% | 47.77% | |
70 Outperform | ¥49.27B | 9.71 | ― | 4.58% | 0.10% | ― | |
69 Neutral | ¥59.57B | 22.79 | ― | 1.67% | -2.91% | ― | |
67 Neutral | ¥59.35B | 13.18 | ― | 2.77% | 8.28% | 0.70% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
Stella Chemifa Corporation announced the disposal of 30,000 treasury shares through a third-party allotment to The Custody Bank of Japan, Ltd., as part of an additional contribution to a share delivery trust for its officers. This move is part of a revised share-based compensation plan aimed at aligning director compensation with company performance, which is expected to enhance corporate value over the medium to long term. The company believes the impact on the market will be minimal due to the reasonable scale of dilution.
Stella Chemifa reported a slight increase in sales revenue for the three months ending June 30, 2025, with significant growth in operating and ordinary profits compared to the previous year. Despite a decline in comprehensive income, the company’s financial position remains stable, with a strong equity-to-asset ratio. The forecast for the fiscal year ending March 31, 2026, anticipates a slight decrease in sales revenue and profits, indicating potential challenges ahead.